84 related articles for article (PubMed ID: 24940695)
21. Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review).
Van den Neste E; Cardoen S; Offner F; Bontemps F
Int J Oncol; 2005 Oct; 27(4):1113-24. PubMed ID: 16142330
[TBL] [Abstract][Full Text] [Related]
22. Resistance to fludarabine-induced apoptosis in Epstein-Barr virus infected B cells.
Fagard R; Mouas H; Dusanter-Fourt I; Devillers C; Bissières P; Martin A; Lenoir G; VanTan H; Feuillard J; Raphaël M
Oncogene; 2002 Jul; 21(29):4473-80. PubMed ID: 12085225
[TBL] [Abstract][Full Text] [Related]
23. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
24. CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation.
de Totero D; Tazzari PL; Capaia M; Montera MP; Clavio M; Balleari E; Foa R; Gobbi M
Haematologica; 2003 Feb; 88(2):148-58. PubMed ID: 12604404
[TBL] [Abstract][Full Text] [Related]
25. Modulation of the human equilibrative nucleoside transporter1 (hENT1) activity by IL-4 and PMA in B cells from chronic lymphocytic leukemia.
Fernández Calotti P; Galmarini CM; Cañones C; Gamberale R; Saénz D; Avalos JS; Chianelli M; Rosenstein R; Giordano M
Biochem Pharmacol; 2008 Feb; 75(4):857-65. PubMed ID: 18078872
[TBL] [Abstract][Full Text] [Related]
26. LMP-420: a novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cells.
Mowery YM; Weinberg JB; Kennedy MN; Bond KM; Moore JO; Lanasa MC; Gockerman JP; Diehl LF; Pizzo SV; Cianciolo GJ; Friedman DR
Leukemia; 2010 Sep; 24(9):1580-7. PubMed ID: 20613784
[TBL] [Abstract][Full Text] [Related]
27. Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells.
Lorkova L; Scigelova M; Arrey TN; Vit O; Pospisilova J; Doktorova E; Klanova M; Alam M; Vockova P; Maswabi B; Klener P; Petrak J
PLoS One; 2015; 10(8):e0135314. PubMed ID: 26285204
[TBL] [Abstract][Full Text] [Related]
28. Multiple forms of nuclear p53 formed in human Raji and MEC1 cells treated with fludarabine.
Henrich S; Christopherson RI
Leukemia; 2008 Mar; 22(3):657-60. PubMed ID: 17728781
[No Abstract] [Full Text] [Related]
29. The role of fludarabine in the treatment of follicular and mantle cell lymphoma.
Lenz G; Hiddemann W; Dreyling M
Cancer; 2004 Sep; 101(5):883-93. PubMed ID: 15329894
[TBL] [Abstract][Full Text] [Related]
30. Correlation of ZAP-70 expression in B cell leukemias to the ex vivo response to a combination of fludarabine/genistein.
Mansour A; Chang VT; Srinivas S; Harrison J; Raveche E
Cancer Immunol Immunother; 2007 Apr; 56(4):501-14. PubMed ID: 17051411
[TBL] [Abstract][Full Text] [Related]
31. Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine.
Ungerechts G; Springfeld C; Frenzke ME; Lampe J; Johnston PB; Parker WB; Sorscher EJ; Cattaneo R
Cancer Res; 2007 Nov; 67(22):10939-47. PubMed ID: 18006839
[TBL] [Abstract][Full Text] [Related]
32. Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine.
de la Fuente MT; Casanova B; Moyano JV; Garcia-Gila M; Sanz L; Garcia-Marco J; Silva A; Garcia-Pardo A
J Leukoc Biol; 2002 Mar; 71(3):495-502. PubMed ID: 11867687
[TBL] [Abstract][Full Text] [Related]
33. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab.
Alas S; Bonavida B; Emmanouilides C
Anticancer Res; 2000; 20(5A):2961-6. PubMed ID: 11062708
[TBL] [Abstract][Full Text] [Related]
34. Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine.
Carew JS; Nawrocki ST; Xu RH; Dunner K; McConkey DJ; Wierda WG; Keating MJ; Huang P
Leukemia; 2004 Dec; 18(12):1934-40. PubMed ID: 15483672
[TBL] [Abstract][Full Text] [Related]
35. Comparative effects of cladribine, fludarabine and pentostatin on nucleotide metabolism in T- and B-cell lines.
Wilson PK; Szabados E; Mulligan SP; Christopherson RI
Int J Biochem Cell Biol; 1998 Jul; 30(7):833-42. PubMed ID: 9722988
[TBL] [Abstract][Full Text] [Related]
36. Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells.
Avramis VI; Nandy P; Kwock R; Solorzano MM; Mukherjee SK; Danenberg P; Cohen LJ
Anticancer Res; 1998; 18(4A):2327-38. PubMed ID: 9703875
[TBL] [Abstract][Full Text] [Related]
37. Apoptosis induction with fludarabine on freshly isolated chronic myeloid leukemia cells.
Zinzani PL; Buzzi M; Farabegoli P; Martinelli G; Tosi P; Zuffa E; Visani G; Testoni N; Salvucci M; Bendandi M
Haematologica; 1994; 79(2):127-31. PubMed ID: 8063259
[TBL] [Abstract][Full Text] [Related]
38. Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2-chlorodeoxyadenosine: a potential marker of defective damage response.
de Viron E; Knoops L; Connerotte T; Smal C; Michaux L; Saussoy P; Vannuffel P; Beert E; Vekemans MC; Hermans C; Bontemps F; Van Den Neste E
Br J Haematol; 2009 Dec; 147(5):641-52. PubMed ID: 19764992
[TBL] [Abstract][Full Text] [Related]
39. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine.
Yamauchi T; Nowak BJ; Keating MJ; Plunkett W
Clin Cancer Res; 2001 Nov; 7(11):3580-9. PubMed ID: 11705880
[TBL] [Abstract][Full Text] [Related]
40. Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.
Nückel H; Frey UH; Röth A; Dührsen U; Siffert W
Eur J Pharmacol; 2005 May; 514(2-3):217-24. PubMed ID: 15910809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
